{"url_path":"/sec/ltrn/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-026696-index.html","accession_number":"0001493152-26-026696","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-026696-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":143,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions\nregarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.\n\n \n\nA\ncopy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the\nSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,\nnor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless\nof any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing."}